In cases of COVID-19 acute respiratory distress syndrome, an excessive host inflammatory
response has been reported, with elevated serum interleukin-6 levels. In this multicenter …

Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …

Patients with coronavirus disease 2019 (COVID‐19) may develop severe respiratory
distress, thought to be mediated by cytokine release. Elevated proinflammatory markers …

Background No therapy is approved for COVID-19 pneumonia. The aim of this study was to
assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and …

Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of
morbidity and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine …

The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in
considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely …

Background Current evidence suggests an important role of the interleukin‐6 (IL‐6) pathway
in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐related cytokine …

Abstract Tocilizumab, an interleukin‐6 inhibitor, may ameliorate the inflammatory
manifestations associated with severe coronavirus disease 2019 (COVID‐19) and thus …

Background Pneumonia with respiratory failure represents the main cause of death in
COVID-19, where hyper inflammation plays an important role in lung damage. This study …

Abstract Coronavirus disease 2019 (COVID‐19) due to infection with severe acute
respiratory syndrome coronavirus 2 causes substantial morbidity. Tocilizumab, an …